Microsoft, weight loss drug sales, and GSK profits surge

Business

In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

As Trump looms large over G20 summit, what can really be achieved by Starmer and Biden in Rio?
Bitcoin rises to fresh record above $94,000 as investors watch Trump transition, ETF options
Honda deploys Peterbilt 579EV electric semi out of Alabama plant
Trump on day one will be ‘like nothing you’ve seen in history’, warns campaign official
Police warning after 13 dangerous dog reports in under 48 hours